Development of new strategies for early diagnosis of mucormycosis from bench to bedside

Thomas J. Walsh, Anna Skiada, Oliver A. Cornely, Emmanuel Roilides, Ashraf Ibrahim, Theoklis Zaoutis, Andreas Groll, Olivier Lortholary, Dimitrios P. Kontoyiannis, George Petrikkos

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Early diagnosis and initiation of amphotericin B (AmB) for treatment of mucormycosis increases survival from approximately 40% to 80%. The central objective of a new study of the European Confederation of Medical Mycology (ECMM) and the International Society for Human and Animal Mycology (ISHAM) Zygomycosis Working Group is to improve the clinical and laboratory diagnosis of mucormycosis. The diagnostic tools generated from this study may help to significantly improve survival from mucormycosis worldwide. The study has three major objectives: to conduct a prospective international registration of patients with mucormycosis using a well-established global network of centres; to construct a predictive risk model for patients at risk for mucormycosis; and to establish an international archive of specimens of tissues, fluids, and organisms linked from the patients enrolled into the registry that will be used for development of leading edge molecular, proteomic, metabolic and antigenic systems for mucormycosis.

Original languageEnglish (US)
Pages (from-to)2-7
Number of pages6
Issue numbers3
StatePublished - Dec 1 2014


  • Diagnosis
  • Epidemiology
  • Mucormycosis
  • Network
  • Zygomycosis

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases


Dive into the research topics of 'Development of new strategies for early diagnosis of mucormycosis from bench to bedside'. Together they form a unique fingerprint.

Cite this